VIVUS to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 4, 2010 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at two investment conferences during the month of November.  

The conference presentation schedule is as follows:

      Credit Suisse 2010 Healthcare Conference

      November 12, 2010 at 9:30 a.m. MST

      Arizona Biltmore Hotel, Phoenix, AZ


      Lazard Capital Markets 7th Annual Healthcare Conference

      November 16, 2010 at 3:10 p.m. EST

      St. Regis Hotel, New York, NY



A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:  






VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris


Brian Korb

Chief Financial Officer


[email protected]

650-934-5200


646-378-2923



SOURCE VIVUS, Inc.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.